Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Open accessThe DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Abstract
Tyrosine kinases are important cellular signaling proteins that have a variety of biological activities including cell proliferation and migration. Multiple kinases are involved in angiogenesis, including receptor tyrosine kinases such as the vascular endothelial growth factor receptor. Inhibition of angiogenic tyrosine kinases has been developed as a systemic treatment strategy for cancer. Three anti-angiogenic tyrosine kinase inhibitors (TKIs), sunitinib, sorafenib and pazopanib, with differential binding capacities to angiogenic kinases were recently approved for treatment of patients with advanced cancer (renal cell cancer, gastro-intestinal stromal tumors, and hepatocellular cancer). Many other anti-angiogenic TKIs are being studied in phase I-III clinical trials. In addition to their beneficial anti-tumor activity, clinical resistance and toxicities have also been observed with these agents. In this manuscript, we will give an overview of the design and development of anti-angiogenic TKIs. We describe their molecular structure and classification, their mechanism of action, and their inhibitory activity against specific kinase signaling pathways. In addition, we provide insight into what extent selective targeting of angiogenic kinases by TKIs may contribute to the clinically observed anti-tumor activity, resistance, and toxicity. We feel that it is of crucial importance to increase our understanding of the clinical mechanism of action of anti-angiogenic TKIs in order to further optimize their clinical efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“Activating mutations of B-Raf are present in approximately 70% of the human melanomas [91, 92].”
BackgroundTumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115 · cited 1×
“Akt/PKB stimulates proliferation and survival by the activation or inhibition of a variety of substrates [31].”
BackgroundSorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 2×
“In addition, it is suggested that chemotherapy and radiation therapy may also directly damage endothelial cells, and thus may enhance antiangiogenic effects [21, 97].”
BackgroundVascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
What Is the Evidence That Tumors Are Angiogenesis Dependent?
Folkman, J. (1990) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/82.1.4 · Cited by 4,531
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774 · cited 1×
“Ligand binding to the extracellular domain of the receptor promotes receptor dimerization, resulting in autophosphorylation of specific tyrosine residues of the cytoplasmic kinase domain [16].”
BackgroundTumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
Angiogenesis in life, disease and medicine
Carmeliet, P. (2005) · Nature · doi:10.1038/nature04478 · Cited by 3,482
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330 · cited 2×
“3b. Activation of Akt/PKB requires generation of phosphatidylinositol 3,4,5-triphosphate (PIP3) by PI3Kmediated phosphorylation of phosphatidylinositol 4,5- biphosphate (PIP2) [30].”
BackgroundVEGF receptor signalling ? in control of vascular function
Olsson, A.-K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1911 · Cited by 3,122 · cited 1×
“Last, but not least, the PI3K pathway seems to be involved in endothelial cell migration [35].”
BackgroundRole of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
Hicklin, D. J., & Ellis, L. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.081 · Cited by 3,007
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953 · cited 2×
“A small fraction of patients fails to show even initial clinical benefit [ 12 ].”
BackgroundMechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625 · cited 1×
“The anti-angiogenic monoclonal antibody bevacizumab blocks the VEGF ligand and inhibits angiogenesis [57].”
BackgroundTargeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
Molecular regulation of vessel maturation
Jain, R. K. (2003) · Nature Medicine · doi:10.1038/nm0603-685 · Cited by 2,529
Role of platelet-derived growth factors in physiology and medicine
Andrae, J., Gallini, R., & Betsholtz, C. (2008) · Genes & Development · doi:10.1101/gad.1653708 · Cited by 2,438
Focal adhesion kinase: in command and control of cell motility.
Mitra, S. K., Hanson, D. A., & Schlaepfer, D. D. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1549 · Cited by 2,335
Angiogenesis: an organizing principle for drug discovery?
Folkman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2115 · Cited by 2,246
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184 · cited 2×
“Furthermore, combining antiangiogenic agents with chemotherapy potentially delays the development of resistance to anti-angiogenic drugs as well as to chemotherapy [ 96 , 98].”
BackgroundMendel, D. B., Laird, A., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R., Abrams, T. J., Ngai, T. J., Lee, L. B., et al. (2003) · PubMed · Cited by 2,157
The fms -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor
de Vries, C., Escobedo, J. A., Ueno, H., Houck, K., Ferrara, N., & Williams, L. T. (1992) · Science · doi:10.1126/science.1312256 · Cited by 2,016
Kerbel, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706596 · Cited by 1,948
The FGF family: biology, pathophysiology and therapy
Beenken, A., & Mohammadi, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2792 · Cited by 1,945 · cited 1×
“Furthermore, it supports proliferation of smooth muscle cells and fibroblasts [24].”
BackgroundMillauer, B., Wizigmann-Voos, S., Schnürch, H., Martinez, R., Møller, N. P. H., Risau, W., & Ullrich, A. (1993) · Cell · doi:10.1016/0092-8674(93)90573-9 · Cited by 1,927
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2130 · Cited by 1,829
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673 · cited 1×
“Besides ‘horizontal’ inhibition of signaling pathways, inhibition in a ‘vertical’ strategy could enhance therapy efficacy; drugs are combined to inhibit a cascade of signaling molecules [74, 89, 90].”
BackgroundVEGF Inhibition and Renal Thrombotic Microangiopathy
Eremina, V., Jefferson, J. A., Kowalewska, J., Hochster, H., Haas, M., Weisstuch, J., Richardson, C., Kopp, J. B., Kabir, M. G., Backx, P. H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707330 · Cited by 1,504
Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system
Augustin, H. G., Young Koh, G., Thurston, G., & Alitalo, K. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2639 · Cited by 1,465
Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
Millauer, B., Shawver, L. K., Plate, K. H., Risaui, W., & Ullrich, A. (1994) · Nature · doi:10.1038/367576a0 · Cited by 1,221
Rational design of inhibitors that bind to inactive kinase conformations
Liu, Y., & Gray, N. S. (2006) · Nature Chemical Biology · doi:10.1038/nchembio799 · Cited by 1,094
Mechanisms of adverse effects of anti-VEGF therapy for cancer
Kamba, T., & McDonald, D. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603813 · Cited by 990
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
Kwak, E. L., Sordella, R., Bell, D. W., Godin-Heymann, N., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Driscoll, D. R., Fidias, P., Lynch, T. J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502860102 · Cited by 952
Wood, J. M., Bold, G., Buchdunger, E., Cozens, R. M., Ferrari, S. M., Frei, J., Hofmann, F., Mestan, J., Mett, H., O'Reilly, T., et al. (2000) · PubMed · Cited by 845
Specificity in Signal Transduction
Pawson, T. (2004) · Cell · doi:10.1016/s0092-8674(03)01077-8 · Cited by 816
Garnett, M. J., & Marais, R. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.022 · Cited by 799
Wedge, S. R., Ogilvie, D., Dukes, M., Kendrew, J., Chester, R., Jackson, J. A., Boffey, S. J., Valentine, P. J., Curwen, J., Musgrove, H. L., et al. (2002) · PubMed · Cited by 798
Heinrich, M. C., Maki, R. G., Corless, C. L., Antonescu, C. R., Harlow, A., Griffith, D., Town, A., Mckinley, A., Ou, W.-B., Fletcher, J. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7461 · Cited by 797
Comparing antibody and small-molecule therapies for cancer
Imai, K., & Takaoka, A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1913 · Cited by 792
Quinn, T. P., Peters, K. G., De Vries, C., Ferrara, N., & Williams, L. T. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.16.7533 · Cited by 754
Takahashi, T. (2001) · The EMBO Journal · doi:10.1093/emboj/20.11.2768 · Cited by 749
Molecular basis for sunitinib efficacy and future clinical development
Faivre, S., Demetri, G., Sargent, W., & Raymond, E. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2380 · Cited by 721
Wedge, S. R., Kendrew, J., Hennequin, L. F., Valentine, P. J., Barry, S. T., Brave, S. R., Smith, N. R., James, N. H., Dukes, M., Curwen, J. O., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4409 · Cited by 714
Engelman, J. A., & Jänne, P. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2248 · Cited by 703
Zachary, I. (2001) · Cardiovascular Research · doi:10.1016/s0008-6363(00)00268-6 · Cited by 662
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
Eisen, T., Ahmad, T., Flaherty, K. T., Gore, M., Kaye, S., Marais, R., Gibbens, I., Hackett, S., James, M., Schuchter, L. M., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603291 · Cited by 644
Hu-Lowe, D. D., Zou, H. Y., Grazzini, M. L., Hallin, M. E., Wickman, G. R., Amundson, K., Chen, J. H., Rewolinski, D. A., Yamazaki, S., Wu, E. Y., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0652 · Cited by 635
Vascular Endothelial Growth Factor Signaling Pathways: Therapeutic Perspective
Kowanetz, M., & Ferrara, N. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1520 · Cited by 564
Hauschild, A., Agarwala, S. S., Trefzer, U., Hogg, D., Robert, C., Hersey, P., Eggermont, A., Grabbe, S., Gonzalez, R., Gille, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7636 · Cited by 548
Receptor tyrosine kinases: mechanisms of activation and signaling
Hubbard, S. R., & Miller, W. T. (2007) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2007.02.010 · Cited by 531
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
Verheul, H. M. W., & Pinedo, H. M. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2152 · Cited by 503
Self-citationGoodman, V. L., Rock, E. P., Dagher, R., Ramchandani, R. P., Abraham, S., Gobburu, J. V. S., Booth, B. P., Verbois, S. L., Morse, D. E., Liang, C. Y., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2328 · Cited by 501
Sorafenib for the Treatment of Advanced Renal Cell Carcinoma
Kane, R. C., Farrell, A. T., Saber, H., Tang, S., Williams, G., Jee, J. M., Liang, C., Booth, B., Chidambaram, N., Morse, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1249 · Cited by 474
Antiangiogenic Therapy: A Universal Chemosensitization Strategy for Cancer?
Kerbel, R. S. (2006) · Science · doi:10.1126/science.1125950 · Cited by 466
Targeted Therapy for Metastatic Renal Cell Carcinoma
Motzer, R. J., & Bukowski, R. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.5415 · Cited by 454
B-RAF is a therapeutic target in melanoma
Karasarides, M., Chiloeches, A., Hayward, R., Niculescu-Duvaz, D., Scanlon, I., Friedlos, F., Ogilvie, L., Hedley, D., Martin, J., Marshall, C. J., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207785 · Cited by 426
Gajiwala, K. S., Wu, J. C., Christensen, J., Deshmukh, G. D., Diehl, W., DiNitto, J. P., English, J. M., Greig, M. J., He, Y.-A., Jacques, S. L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812413106 · Cited by 391
Akt-dependent and -independent mechanisms of mTOR regulation in cancer
Memmott, R. M., & Dennis, P. A. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2009.01.004 · Cited by 382
Targeting the protein kinase C family: are we there yet?
Mackay, H. J., & Twelves, C. J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2168 · Cited by 373
Eskens, F. A. L. M., & Verweij, J. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.09.015 · Cited by 342
Schlumberger, M. J., Elisei, R., Bastholt, L., Wirth, L. J., Martins, R. G., Locati, L. D., Jarzab, B., Pacini, F., Daumerie, C., Droz, J.-P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.7815 · Cited by 340 · cited 2×
“Motesanib (AMG706) VEGFR-1, -2, -3, PDGFR, KIT, RET Lung, thyroid, gallbladder, breast and colorectal cancer, GIST Phase II or III [109, 110]”
BackgroundCiardiello, F., Caputo, R., Damiano, V., Caputo, R., Troiani, T., Vitagliano, D., Carlomagno, F., Veneziani, B. M., Fontanini, G., Bianco, A. R., et al. (2003) · PubMed · Cited by 328
Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers
Widakowich, C., de Castro, G., de Azambuja, E., Dinh, P., & Awada, A. (2007) · The Oncologist · doi:10.1634/theoncologist.12-12-1443 · Cited by 324
Mechanisms of drug inhibition of signalling molecules
Sebolt-Leopold, J. S., & English, J. M. (2006) · Nature · doi:10.1038/nature04874 · Cited by 304
Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor
Zachary, I. (2001) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2001.280.6.c1375 · Cited by 301
VEGF receptor‐2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis
Matsumoto, T., Bohman, S., Dixelius, J., Berge, T., Dimberg, A., Magnusson, P., Wang, L., Wikner, C., Qi, J. H., Wernstedt, C., et al. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600709 · Cited by 292
The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth
Thurston, G., Noguera-Troise, I., & Yancopoulos, G. D. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2130 · Cited by 290
Polverino, A., Coxon, A., Starnes, C., Diaz, Z., DeMelfi, T., Wang, L., Bready, J., Estrada, J., Cattley, R., Kaufman, S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4665 · Cited by 287
Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis
Shibuya, M. (2008) · BMB Reports · doi:10.5483/bmbrep.2008.41.4.278 · Cited by 277
Pathways Mediating Resistance to Vascular Endothelial Growth Factor–Targeted Therapy
Ellis, L. M., & Hicklin, D. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5287 · Cited by 257
Protein kinase inhibitors: contributions from structure to clinical compounds
Johnson, L. N. (2009) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583508004745 · Cited by 256
Bhojani, N., Jeldres, C., Patard, J.-J., Perrotte, P., Suardi, N., Hutterer, G., Patenaude, F., Oudard, S., & Karakiewicz, P. I. (2008) · European Urology · doi:10.1016/j.eururo.2007.11.037 · Cited by 239
Houk, B. E., Bello, C. L., Kang, D., & Amantea, M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1893 · Cited by 231
Podar, K., Tonon, G., Sattler, M., Tai, Y.-T., LeGouill, S., Yasui, H., Ishitsuka, K., Kumar, S., Kumar, R., Pandite, L. N., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609329103 · Cited by 216
Broxterman, H. J., Gotink, K. J., & Verheul, H. M. W. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2009.07.001 · Cited by 209
Self-citationHypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy
Torino, F., Corsello, S. M., Longo, R., Barnabei, A., & Gasparini, G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.4 · Cited by 207
Adams, V. R., & Leggas, M. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.07.022 · Cited by 197
Morabito, A., Piccirillo, M. C., Falasconi, F., De Feo, G., Del Giudice, A., Bryce, J., Di Maio, M., De Maio, E., Normanno, N., & Perrone, F. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0261 · Cited by 196
Role of Nitric Oxide in the Modulation of Angiogenesis
Morbidelli, L., Donnini, S., & Ziche, M. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033391405 · Cited by 192
Intricacies of Bevacizumab-Induced Toxicities and Their Management
Gressett, S. M., & Shah, S. R. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1l426 · Cited by 187
Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity
van Erp, N. P., Eechoute, K., van der Veldt, A. A., Haanen, J. B., Reyners, A. K. L., Mathijssen, R. H. J., Boven, E., van der Straaten, T., Baak-Pablo, R. F., Wessels, J. A. M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.7679 · Cited by 183
Proteins, drug targets and the mechanisms they control: the simple truth about complex networks
Araujo, R. P., Liotta, L. A., & Petricoin, E. F. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2381 · Cited by 172
Schiller, J. H., Larson, T., Ou, S.-H. I., Limentani, S., Sandler, A., Vokes, E., Kim, S., Liau, K., Bycott, P., Olszanski, A. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8355 · Cited by 172
Interaction of Shc with Grb2 Regulates Association of Grb2 with mSOS
Ravichandran, K. S., Lorenz, U., Shoelson, S. E., & Burakoff, S. J. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.2.593 · Cited by 169
Activation of p38 Has Opposing Effects on the Proliferation and Migration of Endothelial Cells
McMullen, M. E., Bryant, P. W., Glembotski, C. C., Vincent, P. A., & Pumiglia, K. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m407060200 · Cited by 160
Are tumours angiogenesis‐dependent?
Verheul, H. M. W., Voest, E. E., & Schlingemann, R. O. (2003) · The Journal of Pathology · doi:10.1002/path.1473 · Cited by 143
Self-citationPazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy.
Sloan, B., & Scheinfeld, N. S. (2008) · PubMed · Cited by 112
Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours
Scott, E. N., Meinhardt, G., Jacques, C. J., Laurent, D., & Thomas, A. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.3.367 · Cited by 104
Verheul, H. M. W., Salumbides, B., Van Erp, K., Hammers, H., Qian, D. Z., Sanni, T., Atadja, P., & Pili, R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4306 · Cited by 103
Self-citationKlein, S., McCormick, F. P., & Levitzki, A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1651 · Cited by 98
van Baal, J. W. P. M., Diks, S. H., Wanders, R. J. A., Rygiel, A. M., Milano, F., Joore, J., Bergman, J. J. G. H. M., Peppelenbosch, M. P., & Krishnadath, K. K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1370 · Cited by 92
Guo, T., Hajdu, M., Agaram, N. P., Shinoda, H., Veach, D. R., Clarkson, B. D., Maki, R. G., Singer, S., DeMatteo, R. P., Besmer, P., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1315 · Cited by 91
Wissner, A., Fraser, H. L., Ingalls, C. L., Dushin, R. G., Floyd, M. B., Cheung, K., Nittoli, T., Ravi, M., Tan, X., & Loganzo, F. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.03.055 · Cited by 87
Vascular Endothelial Growth Factor Signaling Pathways: Therapeutic Perspective
Kowanetz, M., & Ferrara, N. (2008) · AACR Education book · doi:10.1158/aacr.edb-ccr-06-1520 · Cited by 80
Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors.
Mol, C. D., Fabbro, D., & Hosfield, D. J. (2004) · PubMed · Cited by 67
Japanese Study Group on GIST, Nishida, T., Takahashi, T., Nishitani, A., Doi, T., Shirao, K., Komatsu, Y., Nakajima, K., & Hirota, S. (2009) · International Journal of Clinical Oncology · doi:10.1007/s10147-008-0822-y · Cited by 63
Synergistic combinations of signaling pathway inhibitors: Mechanisms for improved cancer therapy
Dent, P., Curiel, D. T., Fisher, P. B., & Grant, S. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2009.03.001 · Cited by 62
Commentary: Novel Therapies for Cancer: Why Dirty Might Be Better
Fojo, T. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0090 · Cited by 59
Current Status of Cediranib: The Rapid Development of a Novel Anti-Angiogenic Therapy
Lindsay, C. R., Macpherson, I. R., & Cassidy, J. (2009) · Future Oncology · doi:10.2217/fon.09.18 · Cited by 43
A single lysis solution for the analysis of tissue samples by different proteomic technologies
Gromov, P., Celis, J. E., Gromova, I., Rank, F. E., Wielenga, V. T., & Moreira, J. M. A. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2008.09.003 · Cited by 36
Cited by
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Gold Nanoparticles in Cancer Treatment
Sztandera, K., Gorzkiewicz, M., & Klajnert-Maculewicz, B. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00810 · Cited by 607
Abdel-Wahab, A. F., Mahmoud, W., & Al-Harizy, R. M. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104511 · Cited by 591
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Ye, F., Dewanjee, S., Li, Y., Jha, N. K., Chen, Z.-S., Kumar, A., Vishakha, Behl, T., Jha, S. K., & Tang, H. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01805-y · Cited by 554
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies
Molinaro, E., Romei, C., Biagini, A., Sabini, E., Agate, L., Mazzeo, S., Materazzi, G., Sellari-Franceschini, S., Ribechini, A., Torregrossa, L., et al. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.76 · Cited by 483
Metadata
- Authors
- Gotink, K. J., & Verheul, H. M. W.
- Venue
- Angiogenesis
- Published
- 2009-12-11
- Volume
- 13
- Issue
- 1
- Pages
- 1-14
- ISSN
- 0969-6970 (ISSN-L)
- 1573-7209
- OpenAlex
- W2067216473
- Cited by
- 501
- References
- 111
- FWCI
- 6.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.